Registered title, quoted from ClinicalTrials.gov
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07241767, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Subjects with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or radiotherapy treatment
Inclusion criterion 2
Chest radiation therapy patients who received>30 Gy within 24 weeks prior to the first use of the investigational drug
Exclusion criterion 13
Pregnant, lactating women, or female participants who plan to become pregnant within 14 months after the last use of the investigational drug during the study period
Exclusion criterion 18
ECOG score is 0 or 1
Inclusion criterion 3
According to the RECIST v1.1 standard, there must be at least one measurable lesion.
Inclusion criterion 5
Suffering from other malignant tumors within the past 5 years
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07241767, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age range: 18-75 years old (including both ends), gender is not limited.
- Subjects with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or radiotherapy treatment
- ECOG score is 0 or 1
- Expected survival period ≥ 12 weeks
- According to the RECIST v1.1 standard, there must be at least one measurable lesion.
- Good level of organ function
- The patient voluntarily joined this study and signed informed consent
- Left ventricular ejection fraction (LVEF) ≥ 50%
Exclusion Criteria:
- Suffering from other malignant tumors within the past 5 years
- Subjects with active central nervous system (CNS) tumor metastasis, a history of meningeal metastasis, or current meningeal metastasis
- Patients with uncontrollable tumor related pain
- Has serious cardiovascular and cerebrovascular diseases
- Significant clinically significant bleeding symptoms occurred within 3 months prior to the first study medication
- Uncontrollable third interstitial fluid accumulation within 2 weeks of initial study medication
- History of clinically significant pulmonary diseases
- Receive other anti-tumor treatments within 4 weeks before the first medication
- Severe infection within 4 weeks before the first medication
- Active, known or suspected autoimmune diseases, and a history of autoimmune diseases.
- History of immunodeficiency
- Individuals with active pulmonary tuberculosis infection within the year prior to enrollment
- Chest radiation therapy patients who received>30 Gy within 24 weeks prior to the first use of the investigational drug
- The adverse reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade I
- Surgical treatment of important organs within 4 weeks prior to the first use of medication
- Use attenuated live vaccine within 28 days prior to the first use of the investigational drug
- There are other serious physical or mental illnesses or laboratory abnormalities present
- Pregnant, lactating women, or female participants who plan to become pregnant within 14 months after the last use of the investigational drug during the study period
- Having bleeding tendency, high risk of bleeding, coagulation dysfunction or thrombophilia tendency
- Previously experienced hypertensive crisis or hypertensive encephalopathy
- Suffering from significant vascular disease within 6 months prior to the first use of medication
- Have undergone a biopsy or other minor surgery within 7 days prior to the first use of medication
- Having severe, unhealed wounds, active ulcers, or untreated fractures
- Gastrointestinal perforation occurred within 6 months prior to the first use of medication
- 24-hour proteinuria quantification ≥ 1g within 7 days before the first medication
- CT/MRI indicates tumor surrounding or invading large blood vessels
Quoted from ClinicalTrials.gov, NCT07241767, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07241767, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.